Abstract
Epidermal growth factor receptor (EGFR) is an anticancer drug target for a number of cancers, such as non-small cell lung cancer. However, unsatisfying treatment effects, terrible side-effects, and development of drug resistance are current insurmountable challenges of EGFR targeting treatments for cancers. With the advancement of nanotechnology, an increasing number of inorganic nanomaterials are applied in EGFR-mediated therapy to improve those limitations and further potentiate the efficacy of molecular targeted cancer therapy. Given their facile preparation, easy modification, and biosecurity, inorganic nanoparticles (iNPs) have been extensively explored in cancer treatments to date. This review presents an overview of the application of some typical metal nanoparticles and nonmetallic nanoparticles in EGFR-targeted therapy, then discusses and summarizes the relevant advantages. Moreover, we also highlight future perspectives regarding their remaining issues. We hope these discussions inspire future research on EGFR-targeted iNPs.
Highlights
Cancer is a major public health problem worldwide (Li et al, 2021a)
The outcomes indicated that Au-Iron oxide nanoparticles (IONPs) nanoprobe provided significant specificity and high sensitivity for both positron emission tomography (PET) and magnetic resonance imaging (MRI) imaging in the human Epidermal growth factor receptor (EGFR)-expressing tumor cells (Figure 4B)
Various advantages of novel inorganic nanoparticles (iNPs) have been identified as multifunctional nanotherapeutics, especially molecular targeted therapy for cancers
Summary
Cancer is a major public health problem worldwide (Li et al, 2021a). The incidence and mortality rates are on the rise year by year all over the world (Bray et al, 2018; Li et al, 2021b; Siegel et al, 2021). Recent years have witnessed the wide application of oncotherapy of iNPs. Due to their particular physico-chemical properties, metallic NPs (MNPs) have been explored in EGFR-targeted therapy to achieve synergistic treatment, improve therapeutic effects, and delay the development of drug resistance. The outcomes showed that 111In-EGFAu-PEG could effectively and target EFGR-positive cancer cells (MDA-MB-468), enhance the tumor uptake, and reduce liver uptake compared to the unlabeled 111In- Au-PEG NPs. Au NPs are qualified for the delivery of EGFR antibodies and cetuximab is the most widely used and reliable EGFR antibody.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
